Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Volume: 369, Issue: 8, Pages: 1201 - 1214
Published: Aug 21, 2013
Abstract
We conducted two integrated randomized, double-blind, placebo-controlled trials of vedolizumab in patients with active disease. In the trial of induction therapy, 374 pa tients (cohort 1) received vedolizumab (at a dose of 300 mg) or placebo intravenously at weeks 0 and 2, and 521 patients (cohort 2) received open-label vedolizumab at weeks 0 and 2, with disease evaluation at week 6. In the trial of maintenance therapy, patients in either cohort...
Paper Details
Title
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Published Date
Aug 21, 2013
Volume
369
Issue
8
Pages
1201 - 1214
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.